News and Trends 30 Apr 2018 Record Series B Financing Supports Antibody Cancer Therapy Crescendo Biologics has raised €57M in in the largest disclosed Series B financing in the European biotech sector this year. The company will use the funds to develop its antibody cancer treatment that activates white blood cells to fight tumors. Crescendo Biologics, based in Cambridge, UK, has raised €57M in the largest disclosed Series B financing for the European […] April 30, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 25 Apr 2018 Cancer Treatment Targeting DNA Repair is Tested in Humans for the First Time Onxeo has initiated a Phase I trial testing its first-in-class cancer treatment that works by inhibiting the repair of tumor DNA. Onxeo, a French biotech, has dosed its first patient in a Phase I study testing its cancer treatment AsiDNA, the first treatment of its kind, for advanced solid tumors. The news follows the Phase […] April 25, 2018 - 1 minutemin - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 23 Apr 2018 The First CAR-T Therapy Is Not Living Up to Commercial Expectations Novartis’ Kymriah, the first approved CAR-T therapy worldwide, has performed far below sales expectations in the last quarter. The news highlights the challenges CAR-T therapies still face before becoming a commercially viable treatment option. CAR-T therapy has shown impressive results treating the cancer of patients for which all other treatments fail. One would expect this […] April 23, 2018 - 3 minutesmins - By Editorial Team Share WhatsApp Twitter Linkedin Email
News and Trends 19 Apr 2018 “This is the First Time CAR-T Has Ever Worked on Acute Myeloid Leukemia“ Celyad has reported clinical results showing the first time a patient has fully recovered from acute myeloid leukemia thanks to a CAR-T therapy, and without the need for chemotherapy preconditioning. At the AACR meeting in Chicago this week, Celyad has presented preliminary data from three of its ongoing Phase 1 clinical trials with a new […] April 19, 2018 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Startup Scout 13 Apr 2018 This Israeli Biotech Targets Protein Translation to Fight Disease Today, we’re taking a look at Anima Biotech, an Israeli company that is developing a new class of drugs that target protein translation to combat a range of diseases, including lung fibrosis, cancer, and Huntington’s disease. Mission: Since 2010, Anima Biotech has been targeting disease-causing proteins with a new class of drugs that control protein translation. […] April 13, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 11 Apr 2018 French CAR-T Developer Raises $164M Despite a Challenging Road Cellectis has raised $164M (€132M) in a follow-on offering to further develop its CAR-T technology in clinical trials, despite having mixed results in the technology’s development up until now. Cellectis, based in Paris, has closed a follow-on offering on NASDAQ, raising a total of around $164M (€132M). The funding will be used to further continue clinical development […] April 11, 2018 - 3 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 29 Mar 2018 Cancer Trial Halted in the UK After Overdosing First Patient Redx Pharma has temporarily interrupted recruitment in a Phase I/IIa cancer trial following “significant adverse events” of its drug on the first patient treated. The first time Redx Pharma’s cancer drug RXC004 has been tested in a patient has resulted in adverse side effects. According to Redx, the dose tested resulted in a higher exposure […] March 29, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 27 Mar 2018 A New Liquid Biopsy Can Improve Ovarian Cancer Diagnosis Angle, a UK-based biotech, is developing a non-invasive liquid biopsy that could be better than current diagnostic methods at predicting ovarian cancer. Angle, a company specializing in liquid biopsies, has shown that its Pelvic Mass Triage (PMT) liquid biopsy test can differentiate between benign and cancerous pelvic masses and ovarian cysts in 95% of cases […] March 27, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 21 Mar 2018 A Personalized Genetic Test for Breast Cancer Arrives in Europe Agendia will launch a next-generation sequencing test in the EU to determine the chances of metastasis in breast cancer patients. Agendia, a US-Dutch biotech specializing in personalized medicine and molecular diagnostics, has obtained CE marking for the MammaPrint BluePrint Kit, a diagnostic device for breast cancer that uses next-generation sequencing technology. The kit can help clinicians identify […] March 21, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 13 Mar 2018 Danish Biotech Collaborates With US Merck on Combination Therapy for Lung Cancer IO Biotech will test its immune modulator in combination with Merck’s checkpoint inhibitor Keytruda, known for curing former US President Jimmy Carter’s cancer. IO Biotech, based in Copenhagen, has entered an agreement with Merck (the US one) to enter a Phase I/II trial for treating lung cancer with IO’s immune modulator, IO102, and Merck’s checkpoint […] March 13, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
In Depth 13 Mar 2018 The Most Important Battle in Gene Editing: CRISPR versus TALEN Despite all the hype, CRISPR is still not in the clinic as a standalone therapy or part of another. So where is it in biotech? CRISPR needs no introduction. Since the gene editing technology first entered the spotlight in 2012 with the promise of revolutionizing gene editing, it has made headlines as the subject of a furious […] March 13, 2018 - 6 minutesmins - By Editorial Team Share WhatsApp Twitter Linkedin Email
News and Trends 1 Mar 2018 Could This Parisian Biotech Startup’s Cancer Treatment Compete With Merck and Novartis? Stimunity, a Parisian biotech, secured a 2M€ seed investment to develop a cancer treatment that could compete with that of big players such as Merck and Novartis. Stimunity is a preclinical-stage startup company which develops drugs targeting a new cell signalling pathway to treat cancer. The company secured funding from Portage, a US-Canadian firm that […] March 1, 2018 - 3 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email